TNBC in the Era of Immunotherapy and Biomarkers

TNBC remains a high-unmet clinical and molecular disorder. Recent investigations have identified several relevant tissue based biomarkers and panels.

The clinical utility of these candidate biomarkers needs to be validated. Chemotherapy is still part of the backbone of management.

The use of platinum agent and PARP inhibitors is an active area of research. The era of cancer immunotherapy incorporation into practice is here, targeted therapies are being studied and needed to advance treatment options.

There is a need for molecular testing to identify actionable biomarkers to assist in precision therapeutics.